No Advantage For Medtronic’s InFuse Versus Bone Graft In Spine Fusion
This article was originally published in The Gray Sheet
Executive Summary
The long-awaited independent analysis of clinical data on Medtronic’s InFuse recombinant human bone morphogenetic protein-2 (rhBMP-2) found no advantages to using it as a substitute for traditional bone grafts in spinal fusion surgery, while also revealing that the risks of rhBMP-2 may be greater than has been previously reported.